Royal Bank of Canada Raises GALAPAGOS NV/S (NASDAQ:GLPG) Price Target to $158.00

GALAPAGOS NV/S (NASDAQ:GLPG) had its target price lifted by Royal Bank of Canada from $152.00 to $158.00 in a research report released on Friday morning, The Fly reports. They currently have a sector perform rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on the company. UBS Group upgraded GALAPAGOS NV/S from a neutral rating to a buy rating in a report on Wednesday, July 31st. Jefferies Financial Group downgraded GALAPAGOS NV/S from a buy rating to a hold rating in a report on Monday, July 29th. BidaskClub upgraded GALAPAGOS NV/S from a hold rating to a buy rating in a report on Thursday, October 31st. Zacks Investment Research downgraded GALAPAGOS NV/S from a buy rating to a hold rating in a report on Thursday, October 31st. Finally, ValuEngine downgraded GALAPAGOS NV/S from a buy rating to a hold rating in a report on Wednesday, October 2nd. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. GALAPAGOS NV/S has a consensus rating of Buy and a consensus target price of $175.88.

Shares of GALAPAGOS NV/S stock traded down $3.92 during trading on Friday, hitting $184.56. 4,987 shares of the company were exchanged, compared to its average volume of 157,765. The company has a quick ratio of 8.95, a current ratio of 8.95 and a debt-to-equity ratio of 0.01. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $192.89. The stock has a market capitalization of $10.07 billion, a price-to-earnings ratio of -278.76 and a beta of 1.58. The firm has a 50 day moving average price of $168.45 and a 200 day moving average price of $151.44.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Thursday, October 24th. The biotechnology company reported $8.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.41) by $10.13. The firm had revenue of $715.97 million during the quarter, compared to the consensus estimate of $52.26 million. GALAPAGOS NV/S had a return on equity of 25.34% and a net margin of 32.09%. Analysts predict that GALAPAGOS NV/S will post 7.17 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in GLPG. Bessemer Group Inc. purchased a new stake in shares of GALAPAGOS NV/S during the 2nd quarter valued at $48,447,000. JPMorgan Chase & Co. grew its stake in shares of GALAPAGOS NV/S by 464.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the biotechnology company’s stock valued at $3,162,000 after buying an additional 20,395 shares during the period. Bank of America Corp DE grew its stake in shares of GALAPAGOS NV/S by 220.6% during the 2nd quarter. Bank of America Corp DE now owns 25,511 shares of the biotechnology company’s stock valued at $3,290,000 after buying an additional 17,554 shares during the period. Caisse DE Depot ET Placement DU Quebec grew its stake in shares of GALAPAGOS NV/S by 134.4% during the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 29,300 shares of the biotechnology company’s stock valued at $3,778,000 after buying an additional 16,800 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of GALAPAGOS NV/S by 35.0% during the 2nd quarter. Victory Capital Management Inc. now owns 32,826 shares of the biotechnology company’s stock valued at $4,232,000 after buying an additional 8,510 shares during the period. 15.37% of the stock is owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: Monthly Dividend Stocks Can Provide Solid Income

The Fly

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.